Kohorst Mira A, Warad Deepti M, Matsumoto Jane M, Heimbach Julie K, El-Youssef Mounif, Arndt Carola A S, Rodriguez Vilmarie, Nageswara Rao Amulya A
Department of Pediatric and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Mayo Clinic, Rochester, MN, USA.
Division of Radiology, Mayo Clinic, Rochester, MN, USA.
Pediatr Transplant. 2017 Sep;21(6). doi: 10.1111/petr.13007. Epub 2017 Jun 20.
HCC is rare in the pediatric population, but is the second most common liver malignancy in children. Survival rates for primary unresectable HCC have been dismal. The objective of this study was to describe our experience with a multimodal approach for the management of unresectable HCC in two adolescent patients and to review the literature. Both patients are currently alive with no recurrence at 51 and 29 months post-transplant. Multimodality treatment involving chemotherapy with doxorubicin, cisplatin, and sorafenib; TACE; timely liver transplantation; and post-transplant therapy with sorafenib and mTOR inhibitors may help improve outcomes and prolong survival in pediatric patients with unresectable HCC.
肝细胞癌在儿童群体中较为罕见，但却是儿童第二常见的肝脏恶性肿瘤。原发性不可切除肝细胞癌的生存率一直很低。本研究的目的是描述我们对两名青少年患者采用多模式方法治疗不可切除肝细胞癌的经验，并回顾相关文献。两名患者目前均存活，移植后51个月和29个月均无复发。多模式治疗包括使用阿霉素、顺铂和索拉非尼进行化疗；经动脉化疗栓塞术；及时进行肝移植；以及移植后使用索拉非尼和雷帕霉素靶蛋白抑制剂进行治疗，这可能有助于改善不可切除肝细胞癌患儿的治疗效果并延长生存期。
